Neonatal alloimmune thrombocytopenia associated with maternal‐fetal incompatibility for blood group B

Curtis, Brian R.; Fick, Andrea; Lochowicz, Andrew J.; McFarland, Janice G.; Ball, Robert H.; Peterson, Julie A.; Aster, Richard H.

doi:10.1111/j.1537-2995.2007.01531.x

Cited by 46 publications

(30 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, HPA‐specific antibodies are only identified in 30% of suspected NAIT cases, while between 20 and 40% of suspected cases have isolated HLA or ABO antibodies, and up to 30% have no identified causative antibody . Case reports confirm that NAIT can be caused by blood group B and A antibodies, though the role of HLA antibodies remains debatable . Clinical criteria that favor NAIT over nonimmune cases include severe thrombocytopenia within 24 hr of birth, as our patient demonstrated.…”

Section: Discussionmentioning

confidence: 57%

MYH9‐macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia

Samelson-Jones

Kramer

Chicka³

et al. 2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

MYH9-related disease is a rare cause of thrombocytopenia. We report an infant girl who presented with severe thrombocytopenia at birth and was initially diagnosed with and treated for neonatal alloimmune thrombocytopenia. However, persistent thrombocytopenia led to the suspicion of congenital thrombocytopenia and subsequent identification of a novel variant in MYH9 (E1421K). In silico analysis strongly predicts that this is a disruptive substitution. Immunofluorescent analysis of neutrophils demonstrates abnormal aggregates of MYH9 protein. This case also suggests that a very high immature platelet fraction (≥40%) may be useful for rapidly differentiating MYH9-related disease from other causes of neonatal thrombocytopenia.

show abstract

Section: Discussionmentioning

confidence: 57%

MYH9‐macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia

Samelson-Jones

Kramer

Chicka³

et al. 2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Antibodies specific for Class I HLA antigens are common in pregnancy and, although such antibodies are widely thought not to cause NAIT, many anecdotal reports suggest that they can do so under some circumstances . Rarely, NAIT can be caused by high‐titer antibodies specific for blood groups A and B or GPIV (CD36) . Further studies of these and other potential explanations for the “diagnostic gap” in NAIT are needed.…”

Section: Discussionmentioning

confidence: 99%

Low‐frequency human platelet antigens as triggers for neonatal alloimmune thrombocytopenia

et al. 2013

Self Cite

View full text Add to dashboard Cite

Background Twenty-four low frequency platelet antigens (HPAs) have been implicated as immunogens in neonatal alloimmune thrombocytopenia (NAIT). We performed studies to define more fully how often these antigens trigger maternal immunization leading to NAIT. Study design and methods In a Phase 1 study, fathers of selected NAIT cases not resolved by serologic testing but thought to have a high likelihood of NAIT on clinical and serologic grounds were typed for low frequency HPAs (LFHPAs) by DNA sequencing. In a Phase 2 study, high-throughput methods were used to type fathers of 1067 consecutive unresolved NAIT cases for LFHPAs. Mothers of 1338 unresolved cases were also typed to assess the prevalence of LFHPAs in a population racially/ethnically similar to the fathers. Results In Phase 1, LFHPAs were identified in 16 of 244 fathers (6.55%). In Phase 2, LFPAs were found in only 28 of 1067 fathers (2.62%). LFHPAs were identified in 27 of 1338 maternal samples (2.01%). HPA-9bw was by far the most common LFHPA identified in the populations studied and was the only LFHPA that was significantly more common in fathers than in mothers of affected infants (P=0.02). Conclusions Maternal immunization against recognized LFHPAs accounts for only a small fraction of the cases of apparent NAIT not resolved by standard serologic testing. Typing of the fathers of such cases for LFHPAs is likely to be rewarding only when a maternal antibody specific for a paternal platelet glycoprotein is demonstrated and/or there is compelling clinical evidence for NAIT.

show abstract

“…Anti -B appeared to be responsible for neonatal alloimmune thrombocytopenia in two group B babies with type 2 HPX platelets and a group O mother with high -titre IgG anti -B [787] .…”

Section: Plateletsmentioning

confidence: 94%

ABO, H, and Lewis Systems

Daniels

2013

Human Blood Groups

View full text Add to dashboard Cite

Neonatal alloimmune thrombocytopenia associated with maternal‐fetal incompatibility for blood group B

Cited by 46 publications

References 30 publications

MYH9‐macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia

MYH9‐macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia

Low‐frequency human platelet antigens as triggers for neonatal alloimmune thrombocytopenia

ABO, H, and Lewis Systems

Contact Info

Product

Resources

About